Sciwind Biosciences Co., Ltd.
Sciwind Biosciences is a privately held peptide-drug developer based in Hangzhou. Its GLP-1 agonist ecnoglutide (XW003) was approved in China in March 2026 for type 2 diabetes and weight management, and the company has since reported adolescent obesity safety data.
| Headquarters | Hangzhou, China |
|---|---|
| Listing | Private |
| Lead asset / stage | ecnoglutide (XW003) Approved — China (type 2 diabetes and weight management) |
| Latest event | Sciwind reported adolescent obesity safety findings for ecnoglutide at EASD 2026. |